Table 1.
Demographic, clinical and histological data of the OS2006 patient cohort included in the present study (n = 108).
| OS2006 Patient Data | Included Patients | |||
|---|---|---|---|---|
| Total | ZA− | ZA+ | p | |
| n = 108 | n = 69 | n = 39 | ||
| Age | ||||
| Med (Range) | 15 (5–50) | 16 (5–48) | 15 (8–50) | 0.7907 |
| <18y | 72 (66.7%) | 48 (69.6%) | 24 (61.5%) | 0.3954 |
| ≥18y | 36 (33.3%) | 21 (30.4%) | 15 (38.5%) | |
| Sex | ||||
| Male | 65 (60.2%) | 42 (60.9%) | 23 (59.0%) | 0.8468 |
| Female | 43 (39.8%) | 27 (39.1%) | 16 (41.0%) | |
| Limb vs. Axial | ||||
| Axial | 12 (11.1%) | 7 (10,1%) | 5 (12.8%) | 0.7534 |
| Limb | 96 (88.9%) | 62 (89.9%) | 34 (87.2%) | |
| Conventional osteosarcoma | ||||
| Chondroblastic | 28 (25.9%) | 20 (29.0%) | 8 (20.5%) | 0.6858 |
| Osteoblastic | 68 (63.0%) | 42 (60.9%) | 26 (66.7%) | |
| Fibroblastic | 6 (5.6%) | 3 (4.3%) | 3 (7.7%) | |
| Other | 6 (5.6%) | 4 (5.8%) | 2 (5.1%) | |
| Meta vs. non meta | ||||
| Localized | 86 (79.6%) | 55 (79.7%) | 31 (79.5%) | 0.9780 |
| Metastases | 22 (20.4%) | 14 (20.3%) | 8 (20.5%) | |
| Chemotherapy | ||||
| API-AI | 13 (12.0%) | 6 (8.7%) | 7 (17.9%) | 0.2180 |
| MTX | 95 (88.0%) | 63 (91.3%) | 32 (82.1%) | |
| Chemotherapy response | ||||
| GR | 67 (65.0%) | 38 (57.6%) | 29 (78.4%) | 0.0336 |
| PR | 36 (35.0%) | 28 (42.4%) | 8 (21.6%) | |
| Missing | 5 | 3 | 2 | |